Latest Operating Expenses News

Cann Group Limited announces a transformative $9 million capital raise alongside a major debt restructure, positioning the medicinal cannabis pioneer for profitability in FY26.

ReadCloud Limited reports a 109% surge in underlying EBITDA to $757k for FY25, driven by robust growth in VET-in-Schools fees and domestic eBook sales, alongside positive cash flow improvements.

OFX Group reports solid progress in migrating corporate clients to its new platform, OFX 2.0, despite a decline in net operating income driven by macroeconomic uncertainty. The fintech’s strategic product launches and client growth signal potential for recovery.

FINEOS Corporation Holdings PLC reports solid Q3 2025 results, highlighting revenue growth, operational efficiencies, and a key North American client migration to its SaaS platform, underpinning positive free cash flow expectations for FY25.

Thor Energy has inked a binding agreement with DISA Technologies to treat uranium waste at its Colorado Projects, leveraging DISA’s newly granted U.S. Nuclear Regulatory Commission license. This deal promises revenue from recovered uranium and critical minerals without upfront costs.

ASX Limited reaffirms its FY26 expense growth guidance while detailing progress on its five-year transformation and addressing regulatory challenges. Strong FY25 financial results and a robust market pipeline underpin the company’s outlook.

ReNerve Limited reported a 38% increase in quarterly sales driven by the launch of its EmpliQ product range and ongoing development of advanced nerve repair technologies. The company’s cash position remains solid as it prepares for upcoming clinical trials.

Bellevue Gold Limited reported robust cash flow for the September quarter, enabling a substantial early repayment on its project loan and maintaining a strong cash position.

Heartland Group Holdings reported a solid first quarter for FY2026, with improved profitability, stable costs, and accelerated realisation of non-strategic assets surpassing expectations.

MedAdvisor Solutions reported a steep 52.8% revenue decline in Q1 FY26, impacted by US regulatory pressures and vaccine program delays, while embarking on a strategic transformation to restore growth.

MedAdvisor reports a sharp 53% drop in 1Q FY26 revenue driven by U.S. regulatory and sector challenges, while advancing a major platform transformation and selling its ANZ business to emerge debt-free.

Imricor Medical Systems made significant regulatory strides with FDA submissions for its MRI-guided cardiac ablation devices and launched NorthStar commercially in Europe, even as it reported increased cash outflows in Q3 CY25.